CD3 Bispecific Antibodies in 2026: Clinical Development, Safety Management, and Future Expansion

Mechanistic and Platform Overview

CD3 bispecific antibodies (also termed T-cell engagers, TCEs) are engineered proteins that simultaneously bind a tumor-associated antigen (TAA) on malignant cells and the CD3 epsilon subunit of the T-cell receptor complex on endogenous T cells. This dual engagement forces the formation of an immunological synapse, redirecting polyclonal T-cell cytotoxicity independently of T-cell antigen specificity, without requiring ex vivo manufacturing 37. Upon synapse formation, T cells undergo activation, proliferation, cytokine secretion, and release of cytolytic proteins — principally perforin and granzyme — resulting in tumor-cell lysis 24.

Two major structural formats dominate the landscape 4. Bispecific T-cell engagers (BiTEs), exemplified by blinatumomab, are small (~55 kDa) Fc-domain-lacking constructs requiring continuous infusion owing to their short half-life. IgG-like bispecific antibodies, such as glofitamab, epcoritamab, teclistamab, and elranatamab, incorporate Fc regions that extend serum half-life and enable intermittent subcutaneous or intravenous dosing. Most currently approved agents employ 1+1 designs (one TAA-binding arm, one CD3-binding arm), with Fc effector functions inactivated to prevent unintended antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Glofitamab uses a bivalent 2+1 design (two CD20-binding arms, one CD3-binding arm), potentially enhancing avidity for the tumor antigen 4. In hematologic malignancies, TAA expression is generally high and relatively uniform across tumor cells, providing a favorable context for TCE activity. Solid-tumor applications face additional barriers including heterogeneous antigen expression, limited T-cell infiltration, immunosuppressive tumor microenvironments, and immunogenicity risks 620.

Clinical Development Landscape in 2026

As of July 2026, multiple CD3 bispecific antibodies have received regulatory approval across hematologic malignancies, with solid-tumor approvals now emerging. Table 1 summarizes approved and late-stage programs by indication, target, company, and regulatory geography.

Table 1. Approved and Late-Stage CD3 Bispecific Antibodies (as of July 2026)

DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; ALL = acute lymphoblastic leukemia; RRMM = relapsed/refractory multiple myeloma; SCLC = small cell lung cancer; R/R = relapsed/refractory; SC = subcutaneous; IV = intravenous 1223242526293031353637

Beyond approved indications, the investigational pipeline is extensive. In follicular lymphoma, TNB-486 (CD19×CD3, AstraZeneca) has reached Phase III in the UK and China. In chronic lymphocytic leukemia (CLL), the highest-stage entries remain Phase II — including epcoritamab, NVG-111 (ROR1×CD3, Novalgen), GNC-035 (CD3/4-1BB/PD-L1/ROR1), and GB-261 (CD20×CD3, Genor) — with no approved CLL entry in the retrieved dataset 23. In mantle cell lymphoma (MCL), glofitamab-gxbm holds a China approval, while mosunetuzumab-axgb is Phase II in the US and UK 23. Early-stage and preclinical programs in China include emfizatamab (CD19/CD3/4-1BB/PD-L1, Phase II), CMG-1A46 (CD20/CD19/CD3, Phase I), and several LintonPharm preclinical candidates 12.

Efficacy Evidence and Clinical Positioning

Lymphoma

The pivotal Phase III STARGLO trial established glofitamab plus GemOx (gemcitabine-oxaliplatin) as a landmark standard in R/R DLBCL, demonstrating an OS hazard ratio (HR) of 0.60, median progression-free survival (PFS) of 13.8 versus 3.6 months, and a complete response (CR) rate of 58.5% versus 25.3% compared with R-GemOx 2. In Phase I/II data, epcoritamab achieved a 63.1% overall response rate (ORR) and 38.9% CR in R/R DLBCL, while glofitamab monotherapy yielded 52% ORR and 39% CR with 67% of CR patients remaining in remission at 18 months 5.

In follicular lymphoma, epcoritamab combined with R2 (lenalidomide-rituximab) demonstrated superior PFS in the Phase III EPCORE FL-1 trial (HR 0.21; p<0.0001). EHA 2026 subgroup data confirmed ORRs of 96.5% (FLIPI 0–2) and 93.0% (FLIPI 3–5) with epcoritamab+R2, compared with 84.8% and 72.6% with R2 alone; CR rates were substantially deeper (86.6% vs 62.1% in FLIPI 0–2; 77.0% vs 35.4% in FLIPI 3–5), with PFS HRs of 0.18 and 0.25, respectively, across subgroups 28. Odronextamab Phase II data showed an FL ORR of 80.5% and CR of 74.2%, and DLBCL ORR of 52%, CR of 31.5% 2. Fixed-duration glofitamab monotherapy data from the Phase III GLOBRYTE trial (presented September 2025) further supports time-limited treatment paradigms 27.

Multiple Myeloma

The foundational MajesTEC-1 trial for teclistamab reported 63% ORR, 39.4% CR or better, and median PFS of 11.3 months in penta-refractory disease 4. Elranatamab (MagnetisMM-3) demonstrated 61% ORR, 35% CR, median PFS of 17.2 months, and OS of 24.6 months in BCMA-naïve RRMM 2. Talquetamab (MonumenTAL-1) showed 64–70% ORR depending on dose schedule 4. Importantly, ASH 2025 MajesTEC-3 data reported >80% response rates in early-relapse settings, supporting line migration toward earlier use 38.

Leukemia and Solid Tumors

Blinatumomab remains the most mature frontline TCE evidence base: adding it to consolidation chemotherapy in newly diagnosed BCR::ABL1-negative B-ALL improved 3-year OS from 68% to 85% (HR 0.41) and relapse-free survival (RFS) from 64% to 80% 2. In R/R adult B-ALL, median OS improved from 4.0 to 7.7 months versus chemotherapy in the Phase III TOWER trial 2. Tarlatamab's approval in SCLC marks the first CD3 bispecific OS benefit demonstrated in a solid tumor, achieving significantly longer OS versus chemotherapy in platinum-pretreated disease 26.

Sequencing with CAR-T and Other Modalities

Both epcoritamab and glofitamab retain activity in post-CAR-T populations (ORRs 54.1% and 35% CR, respectively), enabling their use as rescue therapy 5. CAR-T remains preferred for primary refractory or early-relapsed DLBCL (<12 months), while TCEs serve patients ineligible for leukapheresis/manufacturing, post-CAR-T progression, or requiring rapid off-the-shelf disease control 57. Critically, limited retrospective data suggest prior bispecific exposure may not irreversibly compromise subsequent CAR-T function 5. For non-BCMA sequencing in myeloma, talquetamab (GPRC5D×CD3) retained activity after prior BCMA-directed therapy, and the talquetamab-teclistamab combination showed 78.9% ORR including post-BCMA CAR-T patients 2.

Safety Challenges and Clinical Management

CRS, ICANS, infections, and cytopenias are the cardinal toxicities of TCEs and require structured management protocols. Table 2 summarizes key toxicities and evidence-supported management strategies.

Table 2. Major Toxicities and Management Strategies for CD3 Bispecific Antibodies

231011151619

Step-up dosing is now embedded across all approved TCE platforms and is the primary CRS mitigation strategy. Real-world data from Mayo Clinic (n=58 patients initiating teclistamab outpatient SUD) demonstrated 31.6% CRS incidence (predominantly G1–2), with 54.4% requiring no hospitalization; 60% of SUD administrations were completed in under one hour 3. A condensed step-up schedule (days 1, 3, 5 versus standard days 1, 4, 7) demonstrated comparable CRS rates and median hospitalization of 6 days, with 70% discharged within one week 15. Absence of fever after the first two step-up doses had a negative predictive value of 0.92 for subsequent CRS 15. Outpatient administration of tocilizumab (12 of 18 doses administered at home in one study) and estimated medication cost savings of $115,004 USD per cohort further support outpatient deployment feasibility 22.

Infections represent a particularly prominent challenge in BCMA-directed myeloma therapy, where hypogammaglobulinemia, cumulative immunosuppression from prior therapies, and profound neutropenia converge. Proactive IVIg replacement, infection surveillance, and prophylaxis protocols are now considered standard adjuncts to TCE therapy 216. Anti-drug antibody (ADA) formation complicates solid-tumor TCE deployment (40–52% persistent ADA rates with cibisatamab; 45% with JNJ-78306358), reducing drug exposure and potentially undermining efficacy 613.

Future Expansion and Unresolved Questions

Table 3. Future Development Directions and Associated Challenges

2920212526272838

Antigen escape remains a principal resistance mechanism — including CD19 loss in ALL, CD20 downregulation in lymphoma, and BCMA shedding in myeloma — and is being addressed through multi-target constructs (e.g., CMG-1A46 targeting CD20/CD19/CD3; emfizatamab targeting CD19/CD3/4-1BB/PD-L1) and non-TAA-directed combinations 12. T-cell exhaustion from sustained antigen stimulation raises theoretical concerns for sequential cellular therapies, though limited retrospective data suggest bispecific pre-exposure does not irreversibly compromise subsequent CAR-T engraftment 5. Engineering innovations targeting synaptic geometry and apparent CD3 affinity — demonstrated preclinically for a next-generation ROR1×CD3 construct achieving full tumor killing with dramatically attenuated cytokine release — represent a mechanistic path toward improved safety-efficacy separation 9. Patient-reported outcomes (PROs) remain underutilized in TCE trials; their integration into trial design is increasingly advocated to capture toxicity duration, frequency, and functional impact beyond maximum CTCAE grade — particularly relevant as these agents move into outpatient and earlier-line settings 14.

Conclusion

CD3 bispecific antibodies have unambiguously transitioned from investigational agents to established immunotherapy pillars. As of July 2026, regulatory approvals span BCMA×CD3 and GPRC5D×CD3 agents in multiple myeloma, CD20×CD3 agents in DLBCL and follicular lymphoma, blinatumomab across ALL settings, and tarlatamab marking the class's first solid-tumor survival benefit. The 2025–2026 clinical evidence base — including Phase III STARGLO, EPCORE FL-1, and GLOBRYTE datasets, together with ASH 2025 early-relapse myeloma data — supports expanding use to earlier treatment lines and fixed-duration approaches. Safety management has matured significantly: step-up dosing, premedication, protocolized tocilizumab deployment, outpatient delivery, and proactive infection prophylaxis have collectively reduced treatment-related mortality. Future progress will hinge on solid-tumor expansion (demanding solutions to immunogenicity and microenvironment resistance), biomarker-guided selection, rational combinations, and next-generation molecular engineering to widen the therapeutic index of this transformative immunotherapy class.